NYSE: DGXQuest Diagnostics Inc Stock
$163.80-0.67 (-0.41%)
Updated Apr 17, 2025
DGX Price
$163.80
Fair Value Price
N/A
Market Cap
$18.18B
52 Week Low
$128.38
52 Week High
$178.87
P/E
21.05x
P/B
2.68x
P/S
1.71x
PEG
1.6x
Dividend Yield
1.4%
Revenue
$9.87B
Earnings
$871.00M
Gross Margin
32.9%
Operating Margin
13.62%
Profit Margin
8.8%
Debt to Equity
1.38
Operating Cash Flow
$1B
Beta
0.41
Next Earnings
Apr 21, 2025
Ex-Dividend
Apr 7, 2025
Next Dividend
Apr 21, 2025
DGX Overview
Quest Diagnostics Incorporated operates clinical laboratories in the U.S, Puerto Rico, Mexico, and Brazil. The company also maintains collaborative agreements with hospitals and clinics around the world. The company offers diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, and COVID-19, as well as employment and court-ordered drug testing. Quest Diagnostics was founded in 1967 and is headquartered in Secaucus, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DGX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
DGX
Ranked#16 of 45
Ranked#16 of 45
Be the first to know about important DGX news, forecast changes, insider trades & much more!
DGX News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DGX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DGX ($163.80) is trading above its intrinsic value of $77.82, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DGX is good value based on its earnings relative to its share price (21.05x), compared to the US market average (27.98x)
P/E vs Market Valuation
DGX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more DGX due diligence checks available for Premium users.
Valuation
DGX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
21.05x
Industry
36.04x
Market
27.98x
DGX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DGX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
DGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.68x
Industry
3.26x
DGX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DGX price to earnings growth (PEG)
For valuing profitable companies with growth potential
DGX is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
DGX's financial health
Profit margin
Revenue
$2.6B
Net Income
$222.0M
Profit Margin
8.5%
DGX's Earnings (EBIT) of $1.35B... subscribe to Premium to read more.
Interest Coverage Financials
DGX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$16.2B
Liabilities
$9.3B
Debt to equity
1.38
DGX's short-term assets ($2.39B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DGX's long-term liabilities ($7.17B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DGX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$464.0M
Investing
-$502.0M
Financing
-$170.0M
DGX's operating cash flow ($1.33B)... subscribe to Premium to read more.
Debt Coverage Financials
DGX vs Diagnostic & Research Stocks
Quest Diagnostics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.